Canadian drug developer Milestone Pharmaceuticals (Nasdaq: MIST) today announced positive top-line efficacy and safety data from the Phase III RAPID clinical trial of etripamil, sending the firm’s shares up almost 30% $8.49 in pre-market trading in New York.
The drug is the company's investigational calcium channel blocker, intended for patients with paroxysmal supraventricular tachycardia (PSVT), which a couple of years ago did not achieve its primary endpoint in the NODE-301 Phase III study.
The trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze